Psychiatric Pharmacogenetics Laboratory, Center for Neurobiology and Behavior, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA, United States.
Neurosci Lett. 2011 Oct 10;503(3):200-2. doi: 10.1016/j.neulet.2011.08.035. Epub 2011 Aug 26.
While antidepressant drugs are used to treat generalized anxiety disorder (GAD), patients vary greatly in their treatment response. Evidence shows genetic factors may play a role in treatment response in GAD. We examined whether the BDNF gene, which has been shown to play a role in antidepressant treatment response in major depressive disorder (MDD), also has an effect in GAD. In our study, 155 patients diagnosed with GAD received venlafaxine XR treatment as part of an 18-month relapse prevention study. Genotypes were obtained for the BDNF functional variant rs6265 (Val66Met) for the entire sample (n=155); however, only the European American (EA) population was considered (n=111) for pharmacogenetic analysis. We did not find a significant association between rs6265 and antidepressant treatment response in our GAD population. Future studies in larger populations will need to be conducted to further elucidate the pharmacogenetic role of this variant in anxiety disorders.
虽然抗抑郁药物被用于治疗广泛性焦虑症（GAD），但患者在治疗反应上存在很大差异。有证据表明，遗传因素可能在 GAD 的治疗反应中起作用。我们研究了脑源性神经营养因子（BDNF）基因，该基因已被证明在重度抑郁症（MDD）的抗抑郁治疗反应中起作用，它是否也对 GAD 有影响。在我们的研究中，155 名被诊断为 GAD 的患者接受了文拉法辛 XR 治疗，作为为期 18 个月的复发预防研究的一部分。对整个样本（n=155）进行了 BDNF 功能变体 rs6265（Val66Met）的基因型检测；然而，仅对欧洲裔美国人（EA）人群（n=111）进行了药物遗传学分析。我们没有发现 rs6265 与 GAD 人群中抗抑郁治疗反应之间存在显著关联。未来需要在更大的人群中进行研究，以进一步阐明该变体在焦虑障碍中的药物遗传学作用。
